VIDEO: ‘Interesting’ real-world data on sickle cell treatment from ASH

ByMatthew M. Heeney, MD

ByMarley V. Ghizzone

In this video, Matthew M. Heeney, MD, highlighted “interesting” real-world and long-term follow-up studies for the treatment of sickle cell that were presented at ASH Annual Meeting and Exposition.

“They’re gradually moving out to the phase 2/3, sort of more pivotal, trial range,” Heeney, associate chief of hematology and director of the Sickle Cell Program at Dana-Farber/Boston Children’s Cancer and Blood Disorder Center and associate professor at Harvard Medical School, said.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interview

Disclosures: Heeney reports consulting for AstraZeneca, Cyclerion Therapeutics, Inc., Forma Therapeutics, Inc., Global Blood Therapeutics, Inc., Micelle BioPharma, Novartis Pharmaceuticals Corporation, Pfizer, and Vertex Pharmaceuticals, Inc./CRISPR Therapeutics; and receiving grant or research support from AstraZeneca, Global Blood Therapeutics and Novartis Pharmaceuticals Corporation.

Take Homes in Benign Hematology

Read more

VIDEO: ‘Interesting’ real-world data on sickle cell treatment from ASH

Related Content